A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (NCT02107703)
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.
Who can join: Review the eligibility criteria below.
Location: St. Bernards Medical Center — Jonesboro, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (146 Sites)
Showing the first 25 of 146 sites.
- St. Bernards Medical Center — Jonesboro, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
- University of California - San Diego — La Jolla, California
- Kaiser Permanente — Riverside, California
- Univ of California San Francisco — San Francisco, California
- Stanford University Clinic — Stanford, California
- Palm Beach Cancer Institue — Atlantis, Florida
- Holy Cross Hospital — Fort Lauderdale, Florida
- Florida Cancer Specialists - South — Fort Myers, Florida
- Palm Beach Cancer Institue — Palm Beach Gardens, Florida
- Florida Cancer Specialists - North — St. Petersburg, Florida
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center — Tampa, Florida
- Palm Beach Cancer Institue — Wellington, Florida
- Palm Beach Cancer Institue — West Palm Beach, Florida
- University Cancer & Blood Center, LLC — Athens, Georgia
- Harbin Clinic — Rome, Georgia
- Quincy Medical Group — Quincy, Illinois
- Pharmasite Research, Inc. — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Breslin Cancer Center — Lansing, Michigan
- Minnesota Oncology/Hematology PA — Minneapolis, Minnesota
- Washington University Medical School — City of Saint Peters, Missouri
- Washington University Medical School — Creve Coeur, Missouri
- Freeman Cancer Institute — Joplin, Missouri
- St Lukes Hospital — Kansas City, Missouri
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.